Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Philip Schauer

Bariatric Surgery · PBRC

View

Dr. Justin Hovey, FAAP, FACP, DABOM

Obesity Medicine · Noland Hospital Dothan II

View

Dr. Kimberly Gudzune

Obesity Medicine · JHU

View

Dr. Richard Dutton

General Anesthesiology · UMSOM

View

Dr. Sarah Ro

Obesity Medicine · UNC Health Care

View

Dr. Rebecca Andrews

Primary Care · UCHC

View

Dr. Jed Wolpaw

General Anesthesiology · Johns Hopkins

View

Dr. Matt Sherrer

Perioperative Med · UAB

View

Dr. David Bates

General Internal Medicine · BWH

View

Dr. Reema Dbouk

Obesity Medicine · Emory University

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Precision Medicine and the FDA Modernization Act 2.0: Catalyzing Innovation in Cardiovascular Therapy.

    Nov 3, 2025DOI: 10.1161/circgen.125.005487Journal ArticleAHA

    Written by: Dominic E FullenkampLisa D WilsbacherHanna J TadrosPankaj AroraThomas P Cappola

    Find these authors on Roon

    HT
    Dr. Hanna Tadros
    Peds Heart Failure · BCM

    Disease-specific modeling:

    Genetically mediated DCM, HCM, and ACM each have their own considerations for optimal disease modeling, including culture conditions, loading conditions, cellular sources, cellular make up, proper controls, and the outputs that are properly reflective of human disease. Consensus is evolving for the best approaches to model each cardiomyopathy and will be explored in this session.

    Assessing therapeutics in model systems:

    Current regulatory guidelines call for functional outputs and higher throughput assays as being essential components of NAM methodologies, however gold standards in cardiovascular disease modeling are still being debated and will be discussed in this session.

    The evolving regulatory landscape:

    While regulators are beginning to embrace NAMs, the guidance on the use of NAMs in cardiovascular disease is still evolving. Consideration of the cardiomyopathy type, the known biology, the gene involved, and relevant functional outputs are likely to require comprehensive individualized assessments for regulatory considerations.In the last 20 years, tremendous basic science and clinical research have accelerated the field of precision cardiovascular medicine and laid the foundation for ongoing clinical trials. When coupled with FDA guidance to incorporate NAMs in preclinical testing, precision cardiovascular medicine will likely undergo a rapid evolution as the promise of CRISPR-based therapies and genotype specific therapeutic strategies advance. Critically, strategic collaboration among researchers, regulators, and clinicians will be essential to translate these advances into tangible benefits for patients.
    HTDr. Hanna Tadros

    Dr. Hanna Tadros

    Pediatric Cardiology · Pediatric Heart Failure & Transplantation
    Baylor College of Medicine
    hanna